Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer

Launched by RADIOPHARM THERANOSTICS, LTD · Mar 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the safety of a new treatment called RAD301, which is a type of radioisotope that will be given through an IV. The trial includes both healthy volunteers and patients diagnosed with pancreatic cancer. The goal is to see how safe this treatment is for people in these two groups. To participate, individuals must be willing to provide written consent and meet certain health criteria, such as having acceptable blood test results and being able to tolerate the procedures involved.

Participants will first undergo a screening process that includes a physical exam and blood tests. If they qualify, they will have a PET scan that takes about 5-6 hours in one day. After the scan, participants will return to the clinic two weeks later for further safety checks and will also receive follow-up calls for a month to monitor their health. It's important for potential participants to know that they need to avoid certain substances, like recreational drugs and alcohol, for a specific period before and after the study. Overall, this trial is designed to ensure the safety of RAD301 while providing valuable information about its effects on both healthy individuals and those facing pancreatic cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Must be ≥ 18 years of age at the time of signing the informed consent.
• • 2. All participants must be willing and able to give written informed consent.
• • 3. For patients with PDAC: have a history of histologically or cytologically confirmed PDAC and have had a SOC CT or MRI within 8 weeks prior to signing consent that indicates the presence of at least 1 site of new or residual disease.
• 4. Screening laboratory values within 30 days prior to administration of the study drug:
• • 1. WBC ≥ 1200/μL
• • 2. ANC ≥ 1000/μL
• • 3. Platelets ≥ 75,000/μL
• • 4. Hemoglobin ≥ 9.0 g/dL
• • 5. Creatinine ≤ 1.5 mg/dL
• • 6. AST/ALT ≤ 3 x ULN for patients with no liver metastases.
• • 7. AST/ALT ≤ 5 x ULN for patients with liver metastases.
• • 8. Bilirubin ≤ 1.5 mg/dL except for participants with Gilbert's disease.
• • 5. Patients should have a life expectancy of ≥ 12 weeks as judged by the Investigator.
• • 6. All participants must have baseline pulse oximetry ≥ 95% on room air.
• • 7. Unremarkable ECGs, with PR intervals of less than 200 msec and QTcF intervals (corrected with Frederica's method) of less than 450 msec.
• • 8. Willing to refrain from taking illicit drugs one week prior to PET scanning and for the next 4 weeks after administration of RAD301.
• • 9. Willing to refrain from donating blood for 4 weeks after administration of RAD301.
• • 10. Have not participated in any other research study that requires taking medication for 4 weeks (or 10 half-lives, whichever is longer) prior to study drug administration and for 4 weeks after study drug administration.
• Exclusion Criteria:
• • 1. Participant may not be a member of a vulnerable population defined as participants who are not able to understand the nature of the trial and provide informed consent or who have any medical, psychological or sociological condition that in the opinion of the investigator would interfere with the ability to give consent or interfere with protocol compliance.
• • 2. Women may not be pregnant or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to administration of RAD301.
• • 3. History suggestive of atopia, as indicated by allergies to multiple medications, or foods.
• • 4. History, physical examination, or clinical laboratory tests suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination of RAD301, including chronic liver or renal failure.
• • 5. Unable to tolerate the study procedures.
• • 6. Patients with brain metastases are eligible as long as there is no requirement for high doses of systemic corticosteroids that could result in immunosuppression (\>10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration. An MRI is not required to rule out brain metastases or leptomeningeal metastases
• • 7. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, or interfere with the interpretation of study results.
• • 8. Clinically significant cardiovascular/ cerebrovascular disease defined as cerebral vascular accident, stroke, carotid artery disease transient ischemic attach (\< 6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class \>II) or serious cardiac arrhythmia.
• • 9. Other than PDAC, a prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix or breast.
• • 10. Participants with active, known or suspected autoimmune disease. Participants with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
• • 11. Participants who underwent major surgery within 4 weeks of enrollment (not including diagnostic laparoscopy).